Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

Astellas Pharma Singapore Pte. Ltd.5,589 enrolled

Overview

The purpose of this study is to descriptively evaluate the persistence among adults treated with mirabegron or antimuscarinics in Australia, South Korea and Taiwan. This study will also assess the persistence to the overall Overactive bladder (OAB) treatments of a patient, regardless of treatment discontinuation or switch to other OAB medications.

This study is entirely descriptive using secondary medical claim and pharmacy prescription data. No formal comparisons between users of mirabegron and antimuscarinic will be made. Furthermore, no a priori hypothesis testing is intended.

Study Type

OBSERVATIONAL

Enrollment

5,589

Conditions

Overactive Bladder (OAB)

Interventions

mirabegronDRUG

oral

solifenacinDRUG

oral

darifenacinDRUG

oral

imidafenacinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with a new prescription of the index medication within the index period; * Patient received orally administered monotherapy for OAB on index date. Exclusion Criteria: * Patient with prior dispensing record of the index medication during the pre-index period; * Patient received onabotulinumtoxin A and/or surgical intervention as part of the OAB treatment between the pre index and post-index period; * Patient diagnosed with stress incontinence (International Classification of Diseases-10 (ICD-10) N39.3 or equivalent) or had dispensing record of medication for stress incontinence (duloxetine) before index date; * Patient with urinary tract infection (ICD-10 N30.0 or equivalent) (for National Health Insurance Research Database (NHIRD) and Health Insurance Review and Assessment (HIRA) database) or a co-prescription of any antibiotics (for NostraData) on index date.

Locations (2)

Site AU10000

Sydney, Australia

Site KR82001

Seoul, South Korea

Outcomes

Primary Outcomes

Patients persistence to the index medication

Persistence to the index medication (i.e. mirabegron; solifenacin; darifenacin; imidafenacin; tolterodine; oxybutynin; trospium; fesoterodine; propiverine) is defined as the time to discontinuation during the 1 year post-index period. Days with the index medication for each patient will be calculated as the sum of days of supply per prescription.

Time frame: Up to 12 months

Secondary Outcomes

Patients persistence to the overall Overactive Bladder (OAB) treatment regardless of treatment switching to other OAB medications

Time to discontinuation of the overall OAB treatment during the one-year post-index period (persistence) is defined as days with the index medication (i.e. mirabegron; solifenacin; darifenacin; imidafenacin; tolterodine; oxybutynin; trospium; fesoterodine; propiverine) for each patient and days' supply of any OAB medication will be added up until the grace period exceeds 30 days.

Time frame: Up to 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.